In Brief: revised NDI draft expected in 2013, MusclePharm invests, Sundial label and GMP warnings, AHPA publishes organic guidance
This article was originally published in The Tan Sheet
Executive Summary
CFSAN plans revised NDI draft in 2013; MusclePharm invests in BioZone delivery tech; Indiana kicks off anti-smurfing campaign; Sundial fails basic labeling, GMP compliance; AHPA advises supplement firms on organic rules; Naturex commits to sustainability; Targeted Medical Pharma expands into supplements.
You may also be interested in...
Time's Up For Sundial Herbs – US Firm Recalls All Products Seven Years After FDA’s Warning
FDA officials, following each Sundial Herbs response since 2013 to the agency stating that it had corrected problems identified during inspections, found continued violations on the firm’s website and in its store. Investigators purchased the firm’s products with violative claims as recently as February.
Energy Drinks Swayed By Liquid Supplement Draft Guidance After All
Monster Energy products will transition from supplement to conventional food labeling, in a sign that industry may be adapting to FDA’s draft guidance on liquid supplements that stirred controversy upon its publication in 2009.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”